Jung Eun Park1, Do Sung Lim1,2, Yeong Hee Cho1,2, Kyu Yeong Choi3, Jang Jae Lee3, Byeong C Kim4, Kun Ho Lee1,3, Jung Sup Lee5,6,7. 1. Department of Biomedical Science, College of Natural Sciences, Chosun University, 309 Pilmun-Daero, Gwangju, 61452, Republic of Korea. 2. Department of Integrative Biological Sciences & BK21-Four Educational Research Group for Age-associated Disorder Control Technology, Chosun University, Gwangju, Republic of Korea. 3. Gwangju Alzheimer's disease and related Dementias Cohort Center, Chosun University, Gwangju, Republic of Korea. 4. Department of Neurology, Chonnam National University Medical School, Gwangju, Republic of Korea. 5. Department of Biomedical Science, College of Natural Sciences, Chosun University, 309 Pilmun-Daero, Gwangju, 61452, Republic of Korea. jsplee@chosun.ac.kr. 6. Department of Integrative Biological Sciences & BK21-Four Educational Research Group for Age-associated Disorder Control Technology, Chosun University, Gwangju, Republic of Korea. jsplee@chosun.ac.kr. 7. Gwangju Alzheimer's disease and related Dementias Cohort Center, Chosun University, Gwangju, Republic of Korea. jsplee@chosun.ac.kr.
Abstract
BACKGROUND: Alzheimer's disease (AD) is the most common cause of dementia and most of AD patients suffer from vascular abnormalities and neuroinflammation. There is an urgent need to develop novel blood biomarkers capable of diagnosing Alzheimer's disease (AD) at very early stage. This study was performed to find out new accurate plasma diagnostic biomarkers for AD by investigating a direct relationship between plasma contact system and AD. METHODS: A total 101 of human CSF and plasma samples from normal and AD patients were analyzed. The contact factor activities in plasma were measured with the corresponding specific peptide substrates. RESULTS: The activities of contact factors (FXIIa, FXIa, plasma kallikrein) and FXa clearly increased and statistically correlated as AD progresses. We present here, for the first time, the FXIIa cut-off scores to as: > 26.3 U/ml for prodromal AD [area under the curve (AUC) = 0.783, p < 0.001] and > 27.2 U/ml for AD dementia (AUC = 0.906, p < 0.001). We also describe the cut-off scores from the ratios of CSF Aβ1-42 versus the contact factors. Of these, the representative ratio cut-off scores of Aβ1-42/FXIIa were to be: < 33.8 for prodromal AD (AUC = 0.965, p < 0.001) and < 27.44 for AD dementia (AUC = 1.0, p < 0.001). CONCLUSION: The activation of plasma contact system is closely associated with clinical stage of AD, and FXIIa activity as well as the cut-off scores of CSF Aβ1-42/FXIIa can be used as novel accurate diagnostic AD biomarkers.
BACKGROUND:Alzheimer's disease (AD) is the most common cause of dementia and most of ADpatients suffer from vascular abnormalities and neuroinflammation. There is an urgent need to develop novel blood biomarkers capable of diagnosing Alzheimer's disease (AD) at very early stage. This study was performed to find out new accurate plasma diagnostic biomarkers for AD by investigating a direct relationship between plasma contact system and AD. METHODS: A total 101 of humanCSF and plasma samples from normal and ADpatients were analyzed. The contact factor activities in plasma were measured with the corresponding specific peptide substrates. RESULTS: The activities of contact factors (FXIIa, FXIa, plasma kallikrein) and FXa clearly increased and statistically correlated as AD progresses. We present here, for the first time, the FXIIa cut-off scores to as: > 26.3 U/ml for prodromal AD [area under the curve (AUC) = 0.783, p < 0.001] and > 27.2 U/ml for AD dementia (AUC = 0.906, p < 0.001). We also describe the cut-off scores from the ratios of CSF Aβ1-42 versus the contact factors. Of these, the representative ratio cut-off scores of Aβ1-42/FXIIa were to be: < 33.8 for prodromal AD (AUC = 0.965, p < 0.001) and < 27.44 for AD dementia (AUC = 1.0, p < 0.001). CONCLUSION: The activation of plasma contact system is closely associated with clinical stage of AD, and FXIIa activity as well as the cut-off scores of CSF Aβ1-42/FXIIa can be used as novel accurate diagnostic AD biomarkers.
Authors: Reisa A Sperling; Paul S Aisen; Laurel A Beckett; David A Bennett; Suzanne Craft; Anne M Fagan; Takeshi Iwatsubo; Clifford R Jack; Jeffrey Kaye; Thomas J Montine; Denise C Park; Eric M Reiman; Christopher C Rowe; Eric Siemers; Yaakov Stern; Kristine Yaffe; Maria C Carrillo; Bill Thies; Marcelle Morrison-Bogorad; Molly V Wagster; Creighton H Phelps Journal: Alzheimers Dement Date: 2011-04-21 Impact factor: 21.566
Authors: Clifford R Jack; David S Knopman; William J Jagust; Ronald C Petersen; Michael W Weiner; Paul S Aisen; Leslie M Shaw; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Timothy G Lesnick; Vernon S Pankratz; Michael C Donohue; John Q Trojanowski Journal: Lancet Neurol Date: 2013-02 Impact factor: 44.182
Authors: Sid E O'Bryant; Michelle M Mielke; Robert A Rissman; Simone Lista; Hugo Vanderstichele; Henrik Zetterberg; Piotr Lewczuk; Holly Posner; James Hall; Leigh Johnson; Yiu-Lian Fong; Johan Luthman; Andreas Jeromin; Richard Batrla-Utermann; Alcibiades Villarreal; Gabrielle Britton; Peter J Snyder; Kim Henriksen; Paula Grammas; Veer Gupta; Ralph Martins; Harald Hampel Journal: Alzheimers Dement Date: 2016-11-18 Impact factor: 21.566
Authors: Michael T Heneka; Monica J Carson; Joseph El Khoury; Gary E Landreth; Frederic Brosseron; Douglas L Feinstein; Andreas H Jacobs; Tony Wyss-Coray; Javier Vitorica; Richard M Ransohoff; Karl Herrup; Sally A Frautschy; Bente Finsen; Guy C Brown; Alexei Verkhratsky; Koji Yamanaka; Jari Koistinaho; Eicke Latz; Annett Halle; Gabor C Petzold; Terrence Town; Dave Morgan; Mari L Shinohara; V Hugh Perry; Clive Holmes; Nicolas G Bazan; David J Brooks; Stéphane Hunot; Bertrand Joseph; Nikolaus Deigendesch; Olga Garaschuk; Erik Boddeke; Charles A Dinarello; John C Breitner; Greg M Cole; Douglas T Golenbock; Markus P Kummer Journal: Lancet Neurol Date: 2015-04 Impact factor: 44.182
Authors: Shahid Bashir; Mohammad Uzair; Turki Abualait; Muhammad Arshad; Roaa A Khallaf; Asim Niaz; Ziyad Thani; Woo-Kyoung Yoo; Isaac Túnez; Asli Demirtas-Tatlidede; Sultan Ayoub Meo Journal: Mol Med Rep Date: 2022-02-04 Impact factor: 2.952